Search Results
Your search for The ,The matches 33931 pages
Showing 2451 - 2500Edoxaban Taken for 12 Months May Improve Outcomes in Patients With Cancer and Isolated Distal Deep Vein Thrombosis
Researchers have found that 12 months of the oral factor Xa inhibitor edoxaban may be superior to 3 months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis, according to new findings presented by Yamashita et al at the European Society of Cardiology...
New Clinical Trial Seeks to Reduce Cardiovascular Damage in Patients Undergoing Anticancer Therapy for Breast Cancer
Researchers have launched a new clinical trial examining the effectiveness of behavioral and psychological interventions at reducing cardiovascular damage caused by anticancer therapies in patients with breast cancer. Background Breast cancer—the most common cancer type in the European...
How Is Administrative Payment Burden Associated With Cost-Related Delays in Cancer Care?
Research shows that the United States’ health-care delivery and financing system is so complex that streamlining administrative costs alone could reduce total health-care spending by 15%. In addition, health insurance payment and medical billing processes are time-consuming and expensive for both...
Ibrutinib Included Among the 10 Drugs Slated for Medicare Price Negotiations
On August 29, the Biden Administration announced the first 10 prescription medications that will be included in Medicare’s price negotiations with drug manufacturers as the government aims to reduce the financial burden on millions of older Americans and potentially save the Medicare program...
Divarasib in Patients With Advanced Solid Tumors and a KRAS G12C Mutation
In a phase I study reported in The New England Journal of Medicine, Sacher et al found that the covalent KRAS G12C inhibitor divarasib (also referred to as GDC-6036) produced durable responses in patients with advanced or metastatic solid tumors with a KRAS G12C mutation. In the study, 137 patients ...
Urothelial Carcinoma: Perioperative PD-L1 Inhibition Plus Neoadjuvant Chemotherapy
In a Swiss phase II study (SAKK 06/17) reported in the Journal of Clinical Oncology, Richard Cathomas, MD, and colleagues found that the addition of perioperative durvalumab to neoadjuvant chemotherapy resulted in improved event-free and overall survival in patients with muscle-invasive urothelial...
ER-Positive Breast Cancer: Addition of Adjuvant Ovarian Function Suppression to Tamoxifen in Premenopausal Patients
In an 8-year follow-up of a Korean phase III trial (ASTRRA) reported in the Journal of Clinical Oncology, Baek et al evaluated the effects of adding adjuvant ovarian function suppression to tamoxifen in premenopausal patients with estrogen receptor (ER)-positive breast cancer, with a focus on the...
Are Cannabinoids Safe and Effective for Reducing Symptoms in Pediatric Patients With Cancer?
Investigators have revealed that there may be a lack of evidence to inform the dosing, safety, and efficacy of cannabinoids for managing symptoms in pediatric patients with cancer, according to a recent systematic review and meta-analysis published by Chhabra et al in Cancer. Background Although...
Optimizing Tobacco Cessation Treatment With Lung Cancer Screenings
The Program for Lung Cancer Screening and Tobacco Cessation trial tested different adaptive interventions based on the evidence-based Tobacco Longitudinal Care (TLC) program, in part to learn how best to incorporate TLC into annual lung cancer screening as a smoking cessation standard. The findings ...
Treatment of Relapsed/Refractory Triple-Negative Metastatic Breast Cancer
This is Part 3 of Novel Therapies for Advanced Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Aditya Bardia, Sara Tolaney, and Antonio C. Wolff discuss the treatment of relapsed/refractory triple-negative breast ...
Role of HER2 Expression in Hormone Receptor–Positive Metastatic Breast Cancer
This is Part 2 of Novel Therapies for Advanced Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Aditya Bardia, Sara Tolaney, and Antonio C. Wolff discuss the role of HER2 expression in hormone receptor–positive...
Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
This is Part 1 of Novel Therapies for Advanced Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Aditya Bardia, Sara Tolaney, and Antonio C. Wolff discuss the treatment of hormone receptor–positive, HER2-negative...
FDA Approves Luspatercept-aamt as First-Line Treatment for Adult Patients With Lower-Risk MDS and Anemia Who May Require Transfusions
On August 28, the U.S. Food and Drug Administration (FDA) approved luspatercept-aamt (Reblozyl) to treat anemia in adult patients with very low– to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell transfusions and who have not received previous...
CLL/SLL: Efficacy of CD19-Directed CAR T-Cell Therapy in Relapsed or Refractory Disease
In a phase I/II study (TRANSCEND CLL 004) reported in The Lancet, Tanya Siddiqi, MD, and colleagues found evidence of activity with the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia...
How Guideline-Concordant Are Cancer Treatment Recommendations From ChatGPT?
Researchers have found that about one-third of treatment recommendations from the artificial intelligence (AI) model ChatGPT 3.5 were nonconcordant with the NCCN Clinical Practice Guidelines in Oncology® (NCCN Guidelines®), according to a recent study published by Chen et al in JAMA Oncology. The...
Study Shows Potential of Cabozantinib to Treat Patients With Advanced Neuroendocrine Tumors
An interim analysis of the CABINET trial has shown that the phase III pivotal trial has met its primary endpoint, according to a press release from the Alliance for Clinical Trials in Oncology. Cabozantinib demonstrated statistically significant and clinically meaningful improvements in...
Follow-up of Chronic Immune-Related Adverse Events After Adjuvant Immunotherapy for High-Risk Resected Melanoma
In a retrospective cohort study reported in JAMA Network Open, Goodman et al found that patients receiving adjuvant PD-1 inhibitor therapy for high-risk resected melanoma often had chronic immune-related adverse events, with some persisting over long-term follow-up. Study Details The study included ...
High-Temporal/High-Spatial Resolution Breast MRI for Patients With High Background Parenchymal Enhancement
In a single-center retrospective study reported in the Journal of Clinical Oncology, Eskreis-Winkler et al found that contrast-enhanced magnetic resonance imaging (MRI) using a high-temporal/high-spatial resolution (HTHS) protocol improved breast cancer detection and reduced unnecessary biopsies vs ...
Rural Patients With Cancer: Receipt of Surgical Care at High- vs Low-Volume Hospitals
Patients with cancer who live in rural Pennsylvania counties appear to know that they may have better outcomes if they receive their cancer surgery at a hospital that performs a high volume of those procedures—but many still opt for lower-volume hospitals closer to home when their cancer is likely...
Vorasidenib Improves Progression-Free Survival in IDH1- or IDH2-Mutant Grade 2 Glioma
As reported in The New England Journal of Medicine by Ingo K. Mellinghoff, MD, FACP, and colleagues, the phase III INDIGO trial has shown that vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, significantly improved progression-free survival vs placebo in patients with ...
Adherence to Mediterranean Lifestyle May Be Associated With Lower Risk of All-Cause and Cancer Mortality
Patients who adhere to a Mediterranean lifestyle may have a lower risk of all-cause and cancer mortality, according to a recent study published by Maroto-Rodriguez et al in Mayo Clinic Proceedings. The new findings also indicated that patients who followed the lifestyle’s emphasis on rest,...
Short-Term Use of Immunosuppressants May Not Be Linked to Increased Cancer Risk in Patients With Ocular Inflammatory Diseases
Short-term use of immunosuppressants in patients with ocular inflammatory disease may not be associated with an increased risk of developing cancer, according to a recent study published by Buchanich et al in BMJ Oncology. Background The Systemic Immunosuppressive Therapy for Eye Diseases (SITE)...
Cardiorespiratory Fitness in Youth May Be Associated With a Lower Risk of Nine Cancer Types
Partaking in cardiorespiratory fitness in youth may be associated with up to a 40% lower risk of developing nine cancer types later in life, according to a recent study published by Onerup et al in the British Journal of Sports Medicine. Background Cardiorespiratory fitness—including sustained...
Patterns in Early-Onset Cancer Incidence in the United States From 2010 to 2019
In a study using SEER (Surveillance, Epidemiology, and End Results) registry data reported in JAMA Network Open, Koh et al found that the incidence of cancer among individuals in the United States younger than age 50 years—defined as early-onset cancer—increased significantly between 2010 and 2019. ...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Modified Citrus Pectin Treatment for Nonmetastatic Prostate Cancer
In the long-term treatment phase of an Israeli phase II study reported in the journal Nutrients, Keizman et al found that PectaSol modified citrus pectin (P-MCP) may be effective in patients with nonmetastatic, biochemically relapsed prostate cancer. As stated by the investigators, “[P-MCP] is a...
Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma
Researchers have found that the novel targeted therapy zolbetuximab in combination with a standard chemotherapy may extend survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and overexpression of the claudin-18 isoform 2 protein (CLDN18.2), according to a novel...
Sacituzumab Govitecan-hziy Continues to Show Benefit in Patients With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
The antibody-drug conjugate sacituzumab govitecan-hziy continued to demonstrate superior benefit for patients with hormone receptor–positive, HER2-negative metastatic breast cancer when compared with standard chemotherapy, according to the final analysis of the phase III TROPiCS-02 study published...
Pertuzumab/Trastuzumab With or Without Chemotherapy Followed by T-DM1 in HER2-Positive Metastatic Breast Cancer
In an analysis from a phase II European trial reported in JAMA Oncology, Jens Huober, MD, and colleagues found no difference in overall survival with pertuzumab/trastuzumab, with or without chemotherapy, followed by second-line ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive...
Alcohol Consumption Behaviors Among Patients Diagnosed With Cancer
In a study from the National Institutes of Health All of Us Research Program reported in JAMA Network Open, Shi et al found that alcohol consumption and risky drinking behaviors were common among patients with a cancer diagnosis, including patients currently receiving treatment for their cancer....
Addition of Neoadjuvant Monoclonal Antibody to Platinum-Based Chemotherapy in Resectable NSCLC
In a Chinese phase II trial (TD-FOREKNOW) reported in JAMA Oncology, Lei et al found that the addition of neoadjuvant camrelizumab to platinum-based chemotherapy resulted in a higher pathologic complete response rate among patients with resectable stage IIIA or IIIB (T3N2) non–small cell lung...
Crystal S. Denlinger, MD, FACP, Named New Chief Executive Officer of NCCN
On August 23, 2023, the National Comprehensive Cancer Network® (NCCN) announced Crystal S. Denlinger, MD, FACP, as incoming Chief Executive Officer (CEO). Dr. Denlinger, who is currently Senior Vice President and Chief Scientific Officer of NCCN, will lead the global guidelines organization...
Bariatric Surgery and Cancer Incidence and Mortality for Patients With Severe Obesity
Investigators have demonstrated that bariatric surgery may be associated with a lower incidence of all-cancer and obesity-related cancer among female patients, according to a recent study published by Adams et al in Obesity. The new findings also suggested cancer mortality was significantly reduced ...
Personalized Calculator May Be Predictive of Benefits From Adjuvant TACE in Patients With Hepatocellular Carcinoma Undergoing Hepatectomy
Researchers have developed a personalized calculator that may be capable of predicting the reduced risk of early recurrence in patients with hepatocellular carcinoma, according to a recent study published by Chen et al in eGastroenterology. Background Hepatocellular carcinoma is the most common...
Targeted Axillary Dissection After Neoadjuvant Therapy in Node-Positive Breast Cancer
In a German prospective registry study (SenTa) reported in JAMA Surgery, Kuemmel et al found that targeted axillary dissection alone after neoadjuvant systemic therapy was associated with outcomes similar to those obtained with targeted axillary dissection plus axillary lymph node dissection in...
Follicular Lymphoma: Novel Drug Combination Shows Benefit
In a phase II trial (ROSEWOOD) reported in the Journal of Clinical Oncology, Zinzani et al found that the addition of zanubrutinib to obinutuzumab significantly improved objective response rate among patients with relapsed or refractory follicular lymphoma. Study Details In the open-label trial,...
Abiraterone Acetate With or Without Cabazitaxel in Metastatic Prostate Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Slovin et al found that concomitant abiraterone acetate plus prednisone (AAP) and cabazitaxel appeared to produce better outcomes than AAP followed by cabazitaxel upon disease progression in patients with metastatic...
Developing Solutions for Cancer Care Disparities Across Geography
Understanding the complexities of health disparities within cancer care requires an exploration beyond immediate clinical factors. According to Elisa Rodriguez, PhD, MS, of Roswell Park Comprehensive Cancer Center, Buffalo, New York, geography plays a critical role in defining health outcomes in...
More on the Complexity of Prior Authorization
We read with interest the recent commentary by S. Monica Soni, MD, and Andrew A. Hertler, MD, FACP, on prior authorization (June 10, 2023, issue of The ASCO Post). The nuances of prior authorization in our health-care landscape are both complex and consequential. Conceived as a safeguard against...
How the Cancer Moonshot Aims to Improve the Quality of Life for Adolescent and Young Adult Cancer Survivors
Several recent studies have shown an increasingly disturbing trend: the incidence of early-onset cancers—those diagnosed in individuals younger than age 50—is on the rise, and not just in the United States but globally as well. Worldwide, in 2019, there were a reported 1.19 million new cases of...
Rapid Guideline Update Offers Key Evidence-Based Recommendations for Stage III NSCLC Management
A new ASCO guideline rapid update provides updated recommendations for the management of stage III non–small cell lung cancer (NSCLC). These updated recommendations made by the ASCO expert panel cover treatment options for patients with resected disease and specific genetic mutations as well as...
Noninvasive, Multitarget Stool DNA Methylation Assay Under Study in Early Detection of Multiple Gastrointestinal Cancers
A prospective study in China found that a noninvasive, multitarget stool DNA methylation assay was accurate in the early detection and identification of the tissue of origin of gastrointestinal cancers.1 The study, conducted by Li-Yue Sun, MD, of Guangdong Second Provincial General Hospital,...
Unraveling the Mechanisms Behind the Antichemotherapy Effects of ABCG2 Proteins
Researchers may have discovered how to prevent the cellular-cleaning protein ABCG2 from removing chemotherapeutics from tumor cells, according to a recent study published by Gose et al in Nature Communications. These research findings may improve future cancer therapeutics. Background Most new...
Breast Cancer Screening and 10-Year Net Survival in Canadian Women Aged 40 to 49
In a Canadian study reported in the Journal of Clinical Oncology, Wilkinson et al found that breast cancer screening was associated with greater 10-year breast cancer net survival among women aged 40 to 49 living in jurisdictions including mammography screening programs for this age group, compared ...
Understanding How TET2 Gene Deficiency May Fuel Development of AML
Researchers may have identified how the TET2 gene may fuel rapid cancer growth in patients with acute myeloid leukemia (AML), according to a recent study published by Li et al in Cell Stem Cell. Background AML is distinguished by the rapid division and metastasis of immature leukemia stem cells....
Are All Benzodiazepines Created Equal in Terms of Survival in Patients With Pancreatic Cancer?
Patients with pancreatic cancer who were treated with the benzodiazepine lorazepam had shorter progression-free survival periods than patients who were not, according to study results published by Cornwell et al in Clinical Cancer Research. In contrast, patients who were treated with the...
Researchers May Have Identified Several New Breast Cancer Susceptibility Genes
Researchers have identified genes that may be associated with breast cancer and could eventually be included in tests to identify high-risk patients, according to a recent study published by Wilcox et al in Nature Genetics. Background Currently, genetic tests for breast cancer consider a few genes...
Addition of Neoadjuvant Talimogene Laherparepvec to Surgery in Advanced Melanoma: 5-Year Follow-up
As reported in a research letter in JAMA Oncology by Reinhard Dummer, MD, and colleagues, the final, 5-year analysis of a phase II trial showed continued improvement in outcomes with the addition of neoadjuvant talimogene laherparepvec (T-VEC) to surgery in patients with advanced melanoma. Study...
Rami S. Komrokji, MD, on Myelodysplastic Neoplasms: Classifying Risks Among Subsets of Disease
Rami S. Komrokji, MD, of Moffitt Cancer Center, discusses an assessment of new classifications for myeloid neoplasms and the ongoing efforts to harmonize these classifications, so researchers can better understand risk, outcomes, and survival among patients with genetically distinct types of the...
First-Line Cemiplimab vs Chemotherapy in Advanced NSCLC: 35-Month Follow-up of EMPOWER-Lung 1
As reported in The Lancet Oncology by Özgüroğlu et al, extended follow-up of the phase III EMPOWER-Lung 1 trial has shown continued benefit in overall and progression-free survival with first-line cemiplimab-rwlc vs chemotherapy in patients with advanced non–small cell lung cancer (NSCLC) with...
